Quintiles cuts the ribbon on a new Chinese R&D hub

Quintiles ($Q) has opened up a new, up-sized headquarters in China, toasting the country's growth as a global biopharma power and angling to play a bigger role in its continued evolution.

The outpost, situated in Shanghai's Feng Lin Science Park, is a 43,000-square-foot building that employs about 300 workers with room for 450, Quintiles said. Its opening comes 17 years after the CRO first made its way into Shanghai, giving Quintiles a front-row seat to China's rapid rise to become the world's second-largest market for drug development, founder Dennis Gillings said.

"Today we celebrate not only Quintiles' growth, but also Greater China's emergence as a global player in biopharma R&D," Gillings said in a statement. "Two decades ago we opened in Shanghai with 20 employees across Greater China--now we have more than 1,000."

Quintiles, which has outposts around the world, has increasingly turned its focus to Asia, last month launching a new service specifically catered to small and mid-size biotech companies in the region.

Meanwhile, Quintiles is shooting for between 7% and 8% annual revenue growth in 2015, expecting about $4.5 billion in sales on the year. The CRO dialed back its projections last quarter to account for a strong dollar and an unforeseen jump in cancellations, but the company is counting on its sizable backlog to balance things out as the year goes on.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.